CML: Asciminib Bests Standard TKIs as Frontline Therapy
Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.
Source: medscape.com
Pankit Vachhani News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pankit Vachhani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pankit Vachhani Today - Breaking & Trending Today
Woman living with rare disease shares experience with new treatment
Suki Tipp and her clinician, Dr. Pankit Vachhani, join Marc to share details on the burden of living with indolent systemic mastocytosis and how an appropriate
Source: foxbaltimore.com
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at...
Source: marketscreener.com
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating ...
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose
Source: eagletribune.com